ProfileGDS5678 / 1436091_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 60% 61% 61% 61% 65% 59% 61% 61% 61% 61% 60% 63% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8446764
GSM967853U87-EV human glioblastoma xenograft - Control 23.6007360
GSM967854U87-EV human glioblastoma xenograft - Control 33.64461
GSM967855U87-EV human glioblastoma xenograft - Control 43.6245961
GSM967856U87-EV human glioblastoma xenograft - Control 53.5937561
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9490465
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6392759
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6318761
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6203861
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6473661
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6250261
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5679460
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7515763
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6743362